Viatris reports Q2 2026 revenue of $3.8 billion and raises full-year outlook on strong meloxicam performance.
Viatris raised its 2026 financial outlook after reporting Q2 2026 revenue of $3.8 billion, adjusted EBITDA of $1.2 billion, and adjusted EPS of $0.69. The company cited a strong start to the year and robust demand for its fast-acting meloxicam drug, targeting $500M in peak sales.
Management highlighted an exceptional first half, with revenue and earnings exceeding internal projections. The updated guidance reflects confidence in sustained growth, driven by the drug’s market performance and operational efficiencies.
Shares showed muted reaction in after-hours trading as investors digested the results and revised outlook.